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Dear Sirs,
Multiple myeloma (MM) is characterized by the accumu-
lation of monoclonal plasma cells [12], with common
nervous system involvement including peripheral neurop-
athy and epidural compression [2]. In contrast, intrapa-
renchymal lesions and inﬁltration of cerebrospinal ﬂuid
(CSF) and leptomeninges (meningeal myelomatosis) are
rare; CSF inﬁltration occurs in 1% of MM patients [4],
which is less common than in solid tumours (1–5%) and
much less than in lymphoma and leukaemia (5–15%)
[1, 7]. We present a MM patient with progressive and
stepwise, multifocal neurological symptoms. Craniospinal
MRI was normal, but CSF examination conﬁrmed the
diagnosis of meningeal myelomatosis.
A 63-year-old male visited the emergency department
with double vision and repetitive short-lasting episodes of
light-headedness and headache when standing up without
loss of consciousness. Nine months earlier he had been
diagnosed with Durie-Salmon stage IIIA (International
Scoring System stage 3) IgA-kappa MM, with bone lesions
(skull, spine, long bones) and an extramedullary left psoas
muscle mass. Three cycles of induction chemotherapy with
thalidomide, doxorubicine, and dexamethasone were fol-
lowed by melphalan with stem cell rescue. Four months
later, he experienced a relapse with reoccurrence of the
psoas lesion and new extramedullary (paranasal sinuses
and paravertebral) lesions, for which lenalidomide, dexa-
methasone and radiotherapy of the psoas lesion was
initiated.
At the time of presentation in the emergency depart-
ment, just after initiation of lenalidomide and dexa-
methasone, no abnormalities of ocular motility could be
found although the patient still experienced double vision.
A mild paresis of the right peroneus muscle, hypoesthesia
of the ﬁrst to third right toes, and absent achilles tendon
reﬂexes were noted. Differential diagnosis was broad
(Table 1). Electrocardiography, laboratory investigations
and gadolinium-enhanced brain MRI (Fig. 1a1) were
normal.
One week later, the double vision and light-headedness
had disappeared, but the patient had developed a mild
paresis of the right biceps and triceps muscles with
normal tendon reﬂexes. Because of the multifocal neu-
rological deﬁcits, the revised differential diagnosis
(Table 1) included cervical epidural MM localization and
meningeal myelomatosis. However, CT of the neck and
cervical spine MRI were normal. Right arm electromy-
ography revealed signs consistent with a C5 or C6
radiculopathy.
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arthria and severe weakness of the left anterior tibial
muscle. Lumbar epidural compression, meningeal myelo-
matosis or infection were considered, but gadolinium-
enhanced lumbar spine MRI was normal (Fig. 1a2).
However, CSF examination showed 133910
6 leucocytes/L
and an elevated total protein level of 0.63 g/L; ﬂow
cytometry demonstrated 92% monoclonal plasma cells
(Fig. 1b, c).
We concluded that the patient’s multifocal neurological
abnormalities were due to meningeal myelomatosis. He
was treated with biweekly intrathecal methotrexate and
prednisone. After two courses, no more plasma cells could
be detected in the CSF, CSF leukocyte count (1910
6/L)
and total protein level (0.34 g/L) normalised and his neu-
rological symptoms had improved. Three months later the
patient died from progressive systemic disease. Autopsy
conﬁrmed the diagnosis of meningeal myelomatosis.
In this MM patient, the uncommon occurrence of men-
ingeal myelomatosis was associated with negative cranio-
spinal MRI. This patient’s historystresses that, in cases with
a high clinical suspicion of meningeal myelomatosis, a
normal MRI should be followed by CSF examination.
Symptoms and signs of meningeal myelomatosis are
usually multifocal, including non-speciﬁc prodromes, cra-
nial nerve neuropathy and radiculopathy (all present in our
case) and may vary greatly according to involved struc-
tures. Contrast-enhanced MRI is often used to diagnose
neoplastic meningitis, but sensitivity is much lower for
hematologic malignancies (20–37% for leukaemia and
lymphoma) than for solid tumours (85%) [10]. In contrast,
MRI was false-negative in only 8% of a group of myelo-
matous meningitis patients [8, 9].
There is no standardized treatment for meningeal mye-
lomatosis. Treatment options include craniospinal radiation
or intrathecal chemotherapy, often accompanied by sys-
temic chemotherapy [2, 8, 11, 13], but survival is generally
short [6, 8, 13].
In conclusion, meningeal myelomatosis, although rare,
should be considered in MM patients with progressive
multifocal neurological deﬁcits, even when MRI is normal.
CSF investigation is mandatory in an early stage to prevent
delay in diagnosis and treatment.
Conﬂict of interest N. W. C. J. van de Donk received research
funding from Celgene.
Table 1 Differential diagnosis of neurological complications of multiple myeloma and suggested ancillary investigations for each of these
diagnoses [2, 8, 9, 13]
Causes Diagnosis Ancillary investigation(s)
Directly related to MM 1. Cranial nerve palsy due to skull base lesion(s)
a CT of skull base, cranial ceMRI
2. Spinal epidural localization, resulting in
(a) myelopathy
b
(b) radiculopathy
b
(c) cauda equina syndrome
Spinal MRI
3. Localised plexus or peripheral nerve compression
b Plexus MRI, EMG
4. Amyloid related neuropathy
a EMG, biopsy
5. Central nervous system involvement
(a) intraparenchymal plasmocytoma Brain ceMRI
(b) CSF inﬁltration/meningeal myelomatosis
a, b Craniospinal ceMRI, CSF investigation
6. Obstructive hydrocephalus (due to 5b) [3] Brain CT or MRI
Indirectly related to MM 1. Metabolic encephalopathy (due to hypercalcaemia
a,
uremia, hyperviscosity syndrome)
Serum laboratory investigations
Related to treatment 1. Infection
a Serum laboratory investigations, dedicated
studies for suspected infection
2. Metabolic encephalopathy Serum laboratory investigations
3. Radiation toxicity:
(a) Neuropathy[5]/plexopathy EMG (ceMRI)
(b) myelopathy Spinal ceMRI
(c) encephalopathy Brain ceMRI
4. Chemotherapy-induced peripheral neuropathy
a EMG
ceMRI contrast-enhanced magnetic resonance imaging; CSF cerebrospinal ﬂuid; CT computed tomography; EMG electromyography
a Differential diagnoses at ﬁrst presentation
b Differential diagnoses at second presentation
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Fig. 1 Studies from presented patient. a T1-weighted gadolinium-
enhanced MRI of a1 brain and a2 lumbosacral spine. Pathologically
enhancing multiple myeloma lesions are visible in the sphenoid sinus
(asterisk, a1) and lumbar vertebrae (arrows, a2). No pathological
gadolinium-enhancement of the nerve roots or meninges is visible.
b Microscopic image of cerebrospinal ﬂuid showing the presence of a
myeloma plasma cell with perinuclear halo and eccentrically located
nucleus with prominent nucleoli. c Flow cytometric analysis of
cerebrospinal ﬂuid demonstrating c1 CD138?, c2 CD38?, and c3
CD19- cells, which is typical for malignant plasma cells
J Neurol (2012) 259:1231–1233 1233
123